Aurobindo Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE406A01037
  • NSEID: AUROPHARMA
  • BSEID: 524804
INR
1,215.35
-8.3 (-0.68%)
BSENSE

Dec 05

BSE+NSE Vol: 4.11 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationHalf Yearly Results
Results Snapshot
Figures in Cr
Consolidate Half Yearly Results
Sep'25
Sep'24
Sep'23
Sep'22
Sep'21
Sep'20
Sep'19
Net Sales
16,153.84
15,363.09
14,069.94
11,975.29
11,643.90
12,408.22
11,045.07
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
16,153.84
15,363.09
14,069.94
11,975.29
11,643.90
12,408.22
11,045.07
Raw Material Cost
5,044.96
5,208.51
5,465.74
4,360.45
3,634.89
4,323.34
3,675.85
Purchase of Finished goods
1,653.85
1,427.04
1,211.23
923.73
818.53
1,276.21
1,045.77
(Increase) / Decrease In Stocks
-120.73
-352.60
-285.52
170.55
418.42
-676.43
-54.76
Employee Cost
2,506.13
2,181.43
1,906.94
1,748.63
1,728.78
1,799.89
1,557.05
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Expenses
3,788.11
3,713.00
3,216.95
3,044.66
2,647.18
2,995.05
2,529.76
Total Expenditure (Excl Depreciation)
12,872.32
12,177.38
11,515.34
10,248.02
9,247.80
9,718.06
8,753.67
Operating Profit (PBDIT) excl Other Income
3,281.52
3,185.71
2,554.60
1,727.27
2,396.10
2,690.16
2,291.40
Other Income
225.50
356.93
273.52
97.81
206.48
169.34
31.62
Operating Profit (PBDIT)
3,507.02
3,542.64
2,828.12
1,825.08
2,602.58
2,859.50
2,323.02
Interest
192.99
223.74
124.73
39.92
23.30
36.78
90.83
Exceptional Items
0.00
0.00
-69.75
0.00
0.00
0.00
-25.46
Gross Profit (PBDT)
3,314.03
3,318.90
2,633.64
1,785.16
2,579.28
2,822.72
2,206.73
Depreciation
834.89
786.46
744.06
577.61
573.90
512.86
484.17
Profit Before Tax
2,479.14
2,532.44
1,889.58
1,207.55
2,005.38
2,309.86
1,722.56
Tax
810.39
796.18
566.02
271.60
518.65
686.92
452.13
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
1,668.75
1,736.26
1,323.56
935.95
1,486.73
1,622.94
1,270.43
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
1,668.75
1,736.26
1,323.56
935.95
1,486.73
1,622.94
1,270.43
Share in Profit of Associates
3.58
-1.09
-1.91
-5.20
-20.05
-32.53
4.78
Minority Interest
0.87
1.43
6.28
-0.76
0.28
0.48
0.48
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
1,673.20
1,736.60
1,327.93
929.99
1,466.96
1,590.89
1,275.69
Equity Capital
58.08
58.08
58.59
58.59
58.59
58.59
58.59
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
0.00
30,820.31
0.00
0.00
0.00
0.00
0.00
Earnings per share (EPS)
28.81
29.9
22.66
15.87
25.04
27.15
21.77
Diluted Earnings per share
28.81
29.69
22.57
15.87
25.03
27.15
21.77
Operating Profit Margin (Excl OI)
20.47%
21.09%
18.32%
14.58%
20.69%
22.03%
21.07%
Gross Profit Margin
20.68%
21.97%
18.89%
15.06%
22.27%
23.11%
20.29%
PAT Margin
10.43%
11.49%
9.48%
7.85%
12.66%
13.02%
11.73%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Half Yearly Analysis Highlights
stock-summary

Net Sales

Growth in half year ended Sep 2025 is 5.15% vs 9.19% in Sep 2024

stock-summary

Consolidate Net Profit

Growth in half year ended Sep 2025 is -3.65% vs 30.77% in Sep 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

Growth in half year ended Sep 2025 is 3.01% vs 24.70% in Sep 2024

stock-summary

Interest

Growth in half year ended Sep 2025 is -13.74% vs 79.38% in Sep 2024

stock-summary

Operating Profit Margin (Excl OI)

Growth in half year ended Sep 2025 has fallen from Sep 2024

Compare Half Yearly Results Of Aurobindo Pharma With
Markets Mojo
Figures in Cr
Consolidate Half Yearly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
16,153.84
7,267.51
8,886.33
122.27%
Other Operating Income
0.00
0.00
0.00
Total Operating income
16,153.84
7,267.51
8,886.33
122.27%
Raw Material Cost
5,044.96
1,180.04
3,864.92
327.52%
Purchase of Finished goods
1,653.85
817.94
835.91
102.20%
(Increase) / Decrease In Stocks
-120.73
117.78
-238.51
-202.50%
Employee Cost
2,506.13
1,608.59
897.54
55.80%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
3,788.11
1,775.06
2,013.05
113.41%
Total Expenditure (Excl Depreciation)
12,872.32
5,499.41
7,372.91
134.07%
Operating Profit (PBDIT) excl Other Income
3,281.52
1,768.10
1,513.42
85.60%
Other Income
225.50
171.75
53.75
31.30%
Operating Profit (PBDIT)
3,507.02
1,939.85
1,567.17
80.79%
Interest
192.99
340.33
-147.34
-43.29%
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
3,314.03
1,599.52
1,714.51
107.19%
Depreciation
834.89
440.50
394.39
89.53%
Profit Before Tax
2,479.14
1,159.02
1,320.12
113.90%
Tax
810.39
199.71
610.68
305.78%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
1,668.75
959.31
709.44
73.95%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
1,668.75
959.31
709.44
73.95%
Share in Profit of Associates
3.58
5.49
-1.91
-34.79%
Minority Interest
0.87
-14.97
15.84
105.81%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
1,673.20
949.83
723.37
76.16%
Equity Capital
58.08
41.28
16.80
40.70%
Face Value
1.00
1.00
0.00
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
28.81
23.01
5.80
25.21%
Diluted Earnings per share
28.81
0.00
28.81
Operating Profit Margin (Excl OI)
20.47%
24.33%
0.00
-3.86%
Gross Profit Margin
20.68%
22.01%
0.00
-1.33%
PAT Margin
10.43%
13.28%
0.00
-2.85%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Half Yearly - Net Sales
Net Sales 16,153.84 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is 5.15% vs 9.19% in Sep 2024

Half Yearly - Consolidate Net Profit
Consolidate Net Profit 1,673.20 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is -3.65% vs 30.77% in Sep 2024

Half Yearly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 3,281.52 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is 3.01% vs 24.70% in Sep 2024

Half Yearly - Interest
Interest 192.99 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is -13.74% vs 79.38% in Sep 2024

Half Yearly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 20.47%
in Sep 2025

Figures in %
stock-summary

Growth in half year ended Sep 2025 has fallen from Sep 2024